Dr. Jagannath on Sequencing Therapies for Patients With Multiple Myeloma

Partner | Cancer Centers | <b>The Tisch Cancer Institute</b>

Sundar Jagannath, MD, director of the Multiple Myeloma Program, professor of Medicine (Hematology and Medical Oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses sequencing challenges with therapies for patients with multiple myeloma.

Sundar Jagannath, MD, director of the Multiple Myeloma Program, professor of Medicine (Hematology and Medical Oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses sequencing challenges with therapies for patients with multiple myeloma.

It is imperative to first understand the patient population being treated, Jagannath explains. Oncologists should take into consideration if the patient is elderly, has renal impairment, is experiencing ongoing toxicities from a prior therapy, or has thrombocytopenia. They should also be aware of myeloma-related challenges, including rapidly progressive disease, extramedullary disease, and central nervous system and liver metastases. Exposure to prior therapies should also be considered.

There is no one-size-fits-all approach to selecting or sequencing therapies for patients with myeloma, Jagannath insists.